Durvalumab
Treatment for Tracheal, bronchus, and lung cancer
Typical Dosage: 10 mg/kg IV every 2 weeks or 1500 mg IV every 4 weeks
Effectiveness
80%
Safety Score
35%
Clinical Trials
300
Participants
25K
Comparative Safety Scale(Higher is safer)
Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
35
DangerousModerateSafe
Treatment Details
Dosage Range
10 mg/kg IV every 2 weeks or 1500 mg IV every 4 weeks
Time to Effect
2-4 months
Treatment Duration
Up to 1 year for Stage III consolidation, or until disease progression/unacceptable toxicity
Evidence Quality
HIGHConfidence Score
95%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$140,000
Monitoring:$8,000
Side Effect Mgmt:$10,000
Total Annual:$158,000
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
GOODICER
$60,000/QALY
QALYs Gained
1.62
Outcome-Based Costs
Cost per Responder
$526,667
Cost per Remission
$3,160,000
Comparison vs Placebo/Active Surveillance
Cost Difference
+$140,000/year
More expensive
QALY Difference
+1.62 QALYs
Better outcomes
Dominance
No dominance
Durvalumab Outcomes
for Tracheal, bronchus, and lung cancer
Efficacy Outcomes
Overall Effectiveness
+80%
Response Rate
+30%
Remission Rate
+5%
Common Side Effects
Cough
+30%
Fatigue
+30%
Dyspnea
+20%
Radiation pneumonitis
+15%
Diarrhea
+15%
Rash
+10%
Hypothyroidism
+10%
Sources:
WARNING: LIMITED TRIALS AVAILABLE
You can search for trials, but you probably can't join any because the 1% Treaty hasn't passed yet. Most trials are severely limited by lack of funding and bureaucratic barriers. Help change this!
Active Clinical Trials
No active trials currently recruiting for this treatment
No active trials found in ClinicalTrials.gov